SIGHT — Gensight Biologics SA Income Statement
0.000.00%
Last trade - 00:00
- €26.67m
- €48.07m
- €1.27m
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.7 | 4.39 | 5.28 | 2.58 | 1.27 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 31 | 29.3 | 33.4 | 30.4 | 31 |
Operating Profit | -30.3 | -24.9 | -28.1 | -27.8 | -29.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -30.9 | -34 | -28.6 | -27.6 | -26.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -30.9 | -34 | -28.6 | -27.6 | -26.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -30.9 | -34 | -28.6 | -27.6 | -26.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -30.9 | -34 | -28.6 | -27.6 | -26.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.09 | -0.968 | -0.634 | -0.596 | -0.543 |
Dividends per Share |